Cargando…

DAPA-HF trial signals the birth of ‘diabetic cardiology’ and more

Detalles Bibliográficos
Autores principales:	Wagdy, Kerolos, Selwanos, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Magdi Yacoub Heart Foundation 2020
Materias:	Lessons from the Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768630/ https://www.ncbi.nlm.nih.gov/pubmed/33426039 http://dx.doi.org/10.21542/gcsp.2020.22

Ejemplares similares

The EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support
por: Wagdy, Kerolos
Publicado: (2020)

NEAT HFpEF: Organic nitrates fail to deliver
por: Wagdy, Kerolos, et al.
Publicado: (2016)

ASGR1 - a new target for lowering non-HDL cholesterol
por: Hassan, Mohamed, et al.
Publicado: (2016)

EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction
por: Wagdy, Kerolos, et al.
Publicado: (2021)

DELIVER: Extending the benefits of SGLT-2 inhibitors
por: Samaan, Kerollos, et al.
Publicado: (2023)

Takotsubo cardiomyopathy: A potentially serious trap (Data from the International Takotsubo Cardiomyopathy Registry)
por: Wagdy, Kerolos, et al.
Publicado: (2015)

STOP-HF: Expanding the role of HF programs into the community
por: ElMaghawry, Mohamed, et al.
Publicado: (2014)

BLOCK-HF: CRT gains new ground
por: ElGuindy, Ahmed M., et al.
Publicado: (2013)

PARADIGM-HF: Have we achieved a new paradigm in the treatment of heart failure?
por: Bonow, Robert O., et al.
Publicado: (2014)

Towards tailoring blood pressure control in HFpEF: Lessons from OPTIMIZE-HF
por: Hassan, Mohamed
Publicado: (2019)

STAMPEDE: Bariatric surgery gains more evidence based support
por: Al Suwaidi, Jassim
Publicado: (2014)

ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillation
por: ElMaghawry, Mohamed
Publicado: (2015)

Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA‐HF
por: Adamson, Carly, et al.
Publicado: (2022)

Overview of trials from AHA 2021
por: Gergis, Michael, et al.
Publicado: (2021)

Diabetes and silent atrial fibrillation: A dangerous liaison?
por: Al Suwaidi, Jassim
Publicado: (2014)

Macitentan in pulmonary arterial hypertension: The SERAPHIN trial
por: Said, Karim
Publicado: (2014)

Radial artery as a second conduit gains momentum: The RAPCO trial
por: Simry, Walid, et al.
Publicado: (2021)

The RIME trial: Are we closer to the answer of when to repair ischemic mitral regurgitation?
por: Afifi, Ahmed, et al.
Publicado: (2013)

Transfusion Indication Threshold Reduction (TITRe2) trial: When to transfuse and what to give?
por: Afifi, Ahmed, et al.
Publicado: (2015)

CTS Trials Network: A paradigm shift in the surgical treatment of moderate ischemic mitral regurgitation?
por: Afifi, Ahmed
Publicado: (2015)

Hope for primary cardiovascular prevention with the HOPE (Heart Outcomes Prevention Evaluation)-3 trial findings
por: Suwaidi, Jassim Al
Publicado: (2016)

The Prospective Randomized On-X Valve Anticoagulation Clinical Trial (PROACT): Lower is better, but is it good enough?
por: Bouhout, Ismail, et al.
Publicado: (2019)

TAVI: New trials and registries offer further welcome evidence – U.S. CoreValve, CHOICE, and GARY
por: Pighi, Michele, et al.
Publicado: (2014)

RE-ALIGN: First trial of novel oral anticoagulant in patients with mechanical heart valves – The search continues
por: Shazly, Ahmed, et al.
Publicado: (2014)

CTS Trials Network: Surgical ablation of atrial fibrillation during mitral valve surgery - many questions unanswered
por: Afifi, Ahmed
Publicado: (2015)

COMPARE and Pediatric Heart Network Investigator trials: Losartan finally validated in humans with Marfan, but much work remains!
por: Yacoub, Magdi, et al.
Publicado: (2014)

INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan)
por: Olivotto, Iacopo, et al.
Publicado: (2015)

CADUCEUS, SCIPIO, ALCADIA: Cell therapy trials using cardiac-derived cells for patients with post myocardial infarction LV dysfunction, still evolving
por: Yacoub, Magdi H, et al.
Publicado: (2013)

Clinical trials of bone marrow derived cells for ischemic heart failure. Time to move on? TIME, SWISS-AMI, CELLWAVE, POSEIDON and C-CURE
por: Raynaud, Christophe M., et al.
Publicado: (2013)

Lessons from the first-in-human in vivo CRISPR/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy
por: Kotit, Susy
Publicado: (2023)

Niemann-Pick C1-Like 1 protein: Another target for treatment of dyslipidemia? Evidence from the Myocardial Infarction Genetic Consortium and IMPROVE-IT trials
por: Hassan, Mohamed
Publicado: (2014)

CTS trials network: Rate control vs rhythm control for atrial fibrillation after cardiac surgery - Do bitter pills have blessed effects?
por: Afifi, Ahmed
Publicado: (2016)

CANHEART: Is HDL cholesterol a cardiovascular specific risk factor?
por: Hassan, Mohamed, et al.
Publicado: (2016)

Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF
por: Dewan, Pooja, et al.
Publicado: (2021)

A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)
por: McMurray, John J.V., et al.
Publicado: (2019)

TASTE: To aspirate, or not to aspirate, remains a question
por: Elmahdy, Mahmoud Farouk
Publicado: (2014)

HEAT-PPCI: A clear and welcome win for heparin
por: ElGuindy, Ahmed M.
Publicado: (2014)

SYMPLICITY HTN 3: The death knell for renal denervation in hypertension?
por: Patel, Hitesh C, et al.
Publicado: (2014)

FAME 2 – The best initial strategy for patients with stable coronary artery disease: Do we have an answer at last?
por: ElGuindy, Ahmed M, et al.
Publicado: (2013)

ALDO-DHF & Paramount
por: ElGuindy, Ahmed M
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3525f3lja7r6nvora8ej89o7ot